Abiopharma

Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026

Alto Ingredients, Inc. Completes Transaction to Monetize All 2025 45Z Clean Fuel Production Tax Credits

Fate Therapeutics Appoints Laura Hamill to Board of Directors

RBB Bancorp Announces Authorized Common Stock Repurchase Plan and Partial Redemption of Subordinated Debt

Jet.AI Announces New Record Date for Distribution of SpinCo Shares in Connection with Proposed flyExclusive Transaction

Total Voting Rights and Transaction in Own Shares

Splash Beverage Group Invests in Avicanna, a Leading Cannabinoid Biopharmaceutical Platform, Advancing Its Transformation Into Cannabinoid Healthcare

Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026

LandBridge Forms Special Committee to Evaluate Potential Corporate Conversion

CELSIUS HOLDINGS, INC. INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Celsius Holdings, Inc.’s Directors and Officers for Breach of Fiduciary Duties – CELH